Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Julphar
Argus Health
Federal Trade Commission
Harvard Business School
Deloitte
Medtronic
Chinese Patent Office
Express Scripts
Healthtrust

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,737,112

« Back to Dashboard

Which drugs does patent 7,737,112 protect, and when does it expire?

Patent 7,737,112 protects KYPROLIS and is included in one NDA.

This patent has fifty-four patent family members in twenty countries.
Summary for Patent: 7,737,112
Title:Composition for enzyme inhibition
Abstract: Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.
Inventor(s): Lewis; Evan R. (Pacifica, CA), Ho; Mark Nguyen (San Jose, CA), Fonseca; Fabiana N. (New York, NY)
Assignee: Onyx Therapeutics, Inc. (South San Francisco, CA)
Application Number:11/299,265
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 7,737,112

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-002 Jun 3, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-001 Jul 20, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,737,112

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,088,741 Compounds for enzyme inhibition ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,737,112

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 2260835 ➤ Sign Up
Portugal 2030981 ➤ Sign Up
Portugal 1819353 ➤ Sign Up
South Korea 101299821 ➤ Sign Up
South Korea 20070086924 ➤ Sign Up
Japan 2014141456 ➤ Sign Up
Japan 2012121895 ➤ Sign Up
Japan 2007538081 ➤ Sign Up
Japan 5108509 ➤ Sign Up
Japan 2007537265 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fish and Richardson
Healthtrust
Mallinckrodt
US Department of Justice
Boehringer Ingelheim
Baxter
Teva
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot